RT Journal Article
T1 Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
A1 Bazhenova, Lyudmila
A1 Minchom, Anna
A1 Viteri, Santiago
A1 Bauml, Joshua M.
A1 Ou, Sai-Hong Ignatius
A1 Gadgeel, Shirish M.
A1 Manuel Trigo, Jose
A1 Backenroth, Daniel
A1 Li, Tracy
A1 Londhe, Anil
A1 Mahadevia, Parthiv
A1 Girard, Nicolas
K1 Non-small cell lung cancer
K1 Advanced lung cancer
K1 EGFR mutations
K1 EGFR exon 20 insertions
K1 Flatiron registry
K1 Cell lung-cancer
K1 1st-line treatment
K1 Open-label
K1 Carboplatin-paclitaxel
K1 Phase-iii
K1 Chemotherapy
K1 Afatinib
K1 Adenocarcinoma
K1 Gefitinib
K1 Survival
AB Introduction: Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20 insertion (exon20ins) mutations have not been extensively studied. We conducted a retrospective cohort study to assess the clinical outcomes of EGFR exon20ins compared with common EGFR (cEGFR) mutations. Methods: Adults with advanced NSCLC harboring any EGFR mutations in the NSCLC Flatiron registry (2011 through May 2020) were included. To compare the relative prognosis (prognostic value) of exon20ins vs cEGFR, real-world overall survival (rwOS) was the primary endpoint. Separately, to compare the relative response to tyrosine kinase inhibitor (TKI) treatment (predictive value), real-world progression-free survival (rwPFS) was the primary endpoint. Results: For the prognostic value analysis, 3014 patients with EGFR mutant NSCLC (cEGFR, n = 2833; EGFR exon20ins, n = 181) were eligible. The median (95% CI) rwOS was 16.2 (11.04-19.38) months in the EGFR exon20ins cohort vs 25.5 (24.48-27.04) months in the cEGFR cohort (adjusted HR, 1.75 [1.45-2.131; p
PB Elsevier ireland ltd
SN 0169-5002
YR 2021
FD 2021-11-21
LK https://hdl.handle.net/10668/27958
UL https://hdl.handle.net/10668/27958
LA en
DS RISalud
RD Apr 12, 2025